FGF23 is an early marker of AKI and death after cardiac surgery and in critically ill patients.
Research
An overview of our projects
Publications
A portfolio with a list of our publications
Bio
Get to know more about the PI
Team
Get to know more about our team
The Leaf Lab conducts patient-oriented research in acute kidney injury (AKI) and critical illness. Our goal is to develop novel approaches to prevent AKI, and to improve outcomes in patients who suffer from AKI. Read more about AKI.
Our research is highly collaborative and interdisciplinary and includes:
• Randomized trials
• Biomarker studies
• Genetics
• Epidemiology
News
Top Paper Award
January 27, 2021
Shruti Gupta’s paper entitled, “AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19” was selected as one of the top 5 original research papers published in J Am Soc Nephrol in 2020.
NIH R01 Grant
September 1, 2020
David Leaf was awarded an R01 grant from the NIH/NIDDK for his proposal entitled, “Deferoxamine for the Prevention of Acute Kidney Injury.”
NIH R01 Grant
May 1, 2019
David Leaf was awarded an R01 grant from the NIH/NHLBI for his proposal entitled, “Precision Medicine Approach to Vitamin D3 Administration in Critically Ill Patients.”
Gottschalk Grant
July 1, 2018
David Leaf was awarded a Carl W. Gottschalk Research Scholar Grant to study, “Hepcidin, Dysregulated Iron Homeostasis, and Anemia in Human AKI” from the American Society of Nephrology Foundation for Kidney Research.
